Evolution of the Average Target: Cartesian Therapeutics, Inc.

Evolution of the Target Price: Cartesian Therapeutics, Inc.

Changes in Analyst Recommendations: Cartesian Therapeutics, Inc.

8cfdd46.5uZ7Ob1uaTG9xjCCRKCk9frcutwyT50Jxav477Lv63M.r6wBUuIcUETwgWC0IpDtkrvp8LR_N-9Cr-C-wuiOshK1gj8IhEMLZ_GHaQ~1ddb1407c94e36734cea4df637eb31c6
25-10-21 Cartesian Therapeutics, Inc. Announces Departure of Chief Scientific Officer, Christopher Jewell, Ph.D., Effective November 14, 2025 CI
25-07-09 Wedbush Initiates Cartesian Therapeutics at Outperform With $38 Price Target MT
24-12-19 BTIG Research Initiates Coverage on Cartesian Therapeutics With Buy Rating, $42 Price Target MT
24-08-06 TD Cowen Starts Cartesian Therapeutics With Buy Rating MT
24-07-03 Canaccord Genuity Raises Price Target on Cartesian Therapeutics to $43 From $38, Maintains Buy Rating MT
24-07-03 HC Wainwright Adjusts Price Target on Cartesian Therapeutics to $49 From $54, Maintains Buy Rating MT
24-07-02 Oppenheimer Downgrades Cartesian Therapeutics to Market Perform From Outperform; Shares Tumble MT
24-06-04 Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target MT
24-05-24 Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT
24-04-23 Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
23-08-18 Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating MT
23-08-18 Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating MT
23-03-22 HC Wainwright Adjusts Price Target on Selecta Biosciences to $5 From $4, Maintains Buy Rating MT
23-03-22 Mizuho Securities Adjusts Selecta Biosciences Price Target to $4 From $5, Maintains Buy Rating MT
23-01-31 Canaccord Genuity Adjusts Selecta Biosciences Price Target to $9 From $10, Maintains Buy Rating MT
22-06-21 HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating MT
22-06-14 Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating MT
22-06-06 SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target MT
21-06-15 Selecta Biosciences : BTIG Starts Selecta Biosciences at Buy With $10 Price Target MT
21-03-12 Selecta Biosciences : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform MT
21-01-26 Selecta Biosciences : Mizuho Upgrades Selecta Biosciences to Buy From Neutral, Adjusts Price Target to $8 From $2.50 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+328.33%
+16.56%
+18.28%
+60.95%
+16.05%
+20.37%
+9.35%
+16.93%
-8.21%
+64.19%
Average +54.28%
Weighted average by Cap. +22.48%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.030USD
Average target price
33.67USD
Spread / Average Target
+319.26%
High Price Target
44.00USD
Spread / Highest target
+447.95%
Low Price Target
16.00USD
Spread / Lowest Target
+99.25%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. RNAC Stock
  4. Consensus Cartesian Therapeutics, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!